Tag: Drug pipeline

As of a recent pipeline update, Pfizer had over 100 drug candidates in active development. This extensive portfolio highlights **what drugs does Pfizer have in the pipeline**, showcasing a strategic focus on next-generation medicines and technologies across multiple therapeutic areas.

Approximately one-third of people with depression do not respond to initial antidepressant medications, highlighting a critical need for new treatments. The latest wave of **new antidepressants in Europe** focuses on novel mechanisms to address this unmet need, moving beyond the traditional serotonin and norepinephrine pathways to offer faster and more effective options, particularly for difficult-to-treat cases.

The global AI in drug discovery market was valued at $1.5 billion in 2023 and is projected to soar to $20.30 billion by 2030 [1.9.5]. This explosion in technology is accelerating the hunt for the answer to the question: **what is the next big drug?**

While traditional treatments for vertigo often come with significant side effects like sedation, new and innovative medications are on the horizon. The pressing question for many is, "What is the new medicine for vertigo?"—and the answer points to several promising investigational drugs with novel mechanisms of action, currently advancing through clinical trials.